Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme

BACKGROUND: A novel budesonide orodispersible tablet (BOT) has been proven effective in adult patients with active eosinophilic oesophagitis (EoE) in a 6‐week placebo‐controlled trial (EOS‐1). AIMS: To report the efficacy of an open‐label induction treatment with BOT in a large prospective cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Miehlke, Stephan, Schlag, Christoph, Lucendo, Alfredo J., Biedermann, Luc, Vaquero, Cecilio Santander, Schmoecker, Christoph, Hayat, Jamal, Hruz, Petr, Ciriza de los Rios, Constanza, Bredenoord, Albert Jan, Vieth, Michael, Schoepfer, Alain, Attwood, Stephen, Mueller, Ralph, Burrack, Sarah, Greinwald, Roland, Straumann, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004242/
https://www.ncbi.nlm.nih.gov/pubmed/35412032
http://dx.doi.org/10.1002/ueg2.12220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004242/
https://www.ncbi.nlm.nih.gov/pubmed/35412032
http://dx.doi.org/10.1002/ueg2.12220

Ejemplares similares